Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Aug 25;211(9):1793–1805. doi: 10.1084/jem.20131902

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 Marshall et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 5. — Effect of C3aRA, anti-C5 mAb, and CR2-CD59 treatment on outcome after 70 PHx. Mice were treated with C3aRA or anti-C5 mAb, with or without CR2-CD59 co-treatment, and the following determinations were made 48 h after surgery. (A) Serum ALT. (B) Histological quantification of hepatic necrosis and injury in H&E-stained sections (C) Assessment of liver regeneration by BrdU incorporation, detected by immunohistochemistry and expressed as % positive cells in 10 high-power fields. (D) Survival. Data are combined from 3 independent experiments (n = 8). Results for A–C are expressed as mean ± SEM. ^#, P > 0.05: no significant difference between any complement inhibitor–treated group, assessed by ANOVA.